Targeted Therapies
Our pipeline contains highly targeted mechanisms of action with the potential to become first-in-class medications.
Pipeline
Clinical Stage Pipeline
We are rapidly advancing a rich pipeline of novel targeted therapeutics with broad clinical utility across the areas of Immunology, Immuno-oncology, and Rare Genetic Diseases.
Differentiating Attributes of Our Programs
- Novel mechanisms offering potential as first-in-class medications
- First available therapy and/or substantial improvement over existing therapies for serious diseases
- Targeted mechanisms of action with the potential for a favorable benefit-risk profile
- Candidates for accelerated clinical development and regulatory pathways
- Identified biomarkers and/or published clinical proof of concept increase the probability of regulatory approval
- Associated biomarkers offer the potential for better patient identification and higher response rates